Beilu Pharmaceutical Subsidiary Hichi Pharmaceutical’s Iohexol API Approved for Market Release

Recently, Hichi Pharmaceutical's iopamidol API received the "Approval Notice for the Marketing Application of Chemical APIs" from the National Medical Products Administration. This is another heavyweight product approved for marketing following the approval of iopromide API and iodixanol API.

This not only will further enrich Hichi Pharmaceutical's API product range, drive the steady growth of Hichi Pharmaceutical's API sales business, and continue to enhance the company's market share, but it will also expand the company's integration depth and breadth of API formulations in the contrast agent field. It creates favorable conditions for the company to expand its competitive advantage and market share in the contrast agent domain.